Sector News

Boston Scientific to buy Endo’s urology portfolio for $1.65 billion

March 2, 2015
Life sciences
(Reuters) – Medical device maker Boston Scientific Corp (BSX.N) said it will buy Endo International Plc’s (ENDP.O) American Medical Systems’ men’s and prostate health business for up to $1.65 billion.
 
The purchase ends a nearly decade-long deal drought for Boston Scientific, which has not completed a large takeover since its 2006 acquisition of heart device maker Guidant Corp for $27 billion.
 
The deal value includes additional $50 million in milestone based on 2016 sales, Boston Scientific said on Monday.
 
AMS’ men’s and prostate health businesses, which generated 2014 sales of about $400 million, provides treatments for conditions such as erectile dysfunction, enlarged prostate and bladder leakage.
 
Reuters reported last week that Boston Scientific was close to buying Endo’s AMS medical device unit.
 
Monday’s deal, which is expected to close in the third quarter of 2015, does not include AMS’ women’s health business.
 
Endo said in a separate statement it is evaluating strategic alternatives for the business.
 
Boston Scientific said it will finance the deal through a combination of existing and newly committed credit facilities.
 
BofA Merrill Lynch is Endo’s financial adviser and Skadden Arps Slate Meagher & Flom LLP the legal adviser.
 
J.P. Morgan Securities is financial adviser to Boston Scientific.
 
(Reporting by Ankur Banerjee in Bengaluru; Editing by Savio D’Souza)

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend